MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
Key Highlights
- ➤MacroGenics (MGNX) doses first patient in Phase 1 MGC030 solid-tumor study
- ➤MGC030 becomes MacroGenics’ third ADC in active clinical development
- ➤Phase 1 dose-escalation study may enroll up to 54 participants
- ➤MGC030 targets an undisclosed antigen with no approved therapies
Expert Statements
Ezio Bonvini, Senior Vice President and Chief Scientific Officer of MacroGenics
“MGC030 demonstrated encouraging antitumor activity in multiple preclinical models, and we look forward to advancing this product candidate through the Phase 1 study. We expect that this trial will deepen our understanding of how the molecule may help address the unmet needs of patients with selected advanced solid tumors”
Ezio Bonvini, Senior Vice President and Chief Scientific Officer of MacroGenics
“The dosing of a first patient with MGC030 builds upon the strong early-stage clinical momentum we have sustained across our innovative ADC pipeline, as this molecule is now our third ADC in active clinical development.”
ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1 study of MGC030, a first-in-class antibody-drug conjugate (ADC) directed against an undisclosed target, in patients with advanced solid tumors.
“MGC030 demonstrated encouraging antitumor activity in multiple preclinical models, and we look forward to advancing this product candidate through the Phase 1 study. We expect that this trial will deepen our understanding of how the molecule may help address the unmet needs of patients with selected advanced solid tumors,” said Ezio Bonvini, M.D., Senior Vice President and Chief Scientific Officer of MacroGenics. “The dosing of a first patient with MGC030 builds upon the strong early-stage clinical momentum we have sustained across our innovative ADC pipeline, as this molecule is now our third ADC in active clinical development.”
Get started
Create a free account to read the full story.